Skip to Content
Reach blood sugar goals with long-acting insulin. Go >

Insulin inhalation, rapid acting Disease Interactions

There are 6 disease interactions with insulin inhalation, rapid acting:

Major

Inhaled Insulin (Includes Insulin inhalation, rapid acting) ↔ Acute Bronchospasm

Severe Potential Hazard, Moderate plausibility

Applies to: Chronic Obstructive Pulmonary Disease, Asthma

The use of inhaled insulin is contraindicated in patients with chronic lung disease such as asthma and COPD. Acute bronchospasm has been observed after an inhaled insulin dosage. Prior to initiating therapy with an inhaled insulin product it is recommended to evaluate all patients medical history, physical examination and spirometry (FEV1) to identify potential underlying lung disease.

Moderate

Inhaled Insulin (Includes Insulin inhalation, rapid acting) ↔ Diabetic Ketoacidosis

Moderate Potential Hazard, Moderate plausibility

Applies to: Diabetic Ketoacidosis, Diabetes Type 1, Infection - Bacterial/Fungal/Protozoal/Viral

Rapid acting inhaled insulin may predispose certain patients to develop diabetic ketoacidosis (DKA). In clinical trials, subjects with type 1 diabetes receiving inhaled insulin were more likely to develop DKA than patients receiving comparator agents. It is recommended to increase the frequency of glucose monitoring and to consider using an alternate route of administration, if appropriate, in patients at risk for DKA, such as patients with an acute illness or infections.

Moderate

Inhaled Insulin (Includes Insulin inhalation, rapid acting) ↔ Lung Cancer

Moderate Potential Hazard, Moderate plausibility

Applies to: Lung Cancer

In clinical trials, lung cancer was observed in smoker and non-smoker patients using inhaled insulin. In patients with active lung cancer, a prior history of lung cancer, or in patients at risk for lung cancer, it is recommended to consider whether the benefits of inhaled insulin use outweigh this potential risk.

Moderate

Insulin (Includes Insulin inhalation, rapid acting) ↔ Renal/Liver Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease, Renal Dysfunction

Insulin requirements may be diminished in patients with renal or hepatic impairment due to reduced insulin metabolism and, in the latter case, also to reduced capacity for gluconeogenesis. Lower initial dosages may be appropriate, with careful monitoring of plasma glucose levels and dosing adjustments.

References

  1. "Product Information. Novolog (insulin aspart)" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
  2. "Product Information. Lantus (insulin glargine)" Aventis Pharmaceuticals, Swiftwater, PA.
  3. "Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.
Moderate

Insulin- Hypokalemia

Moderate Potential Hazard, Moderate plausibility

Applies to: Hypokalemia

Hypokalemia may commonly occur during treatment with insulin. Use with caution in patients who may be particularly at risk of developing hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).

Moderate

Insulin/Oral Hypoglycemic Agents (Includes Insulin inhalation, rapid acting) ↔ Hypoglycemia

Moderate Potential Hazard, Moderate plausibility

Applies to: Adrenal Insufficiency, Malnourished, Autonomic Neuropathy, Panhypopituitarism, Anorexia/Feeding Problems

Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents. Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.

References

  1. "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.
  2. Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):
  3. "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.
View all 15 references

insulin inhalation, rapid acting drug Interactions

There are 860 drug interactions with insulin inhalation, rapid acting

insulin inhalation, rapid acting alcohol/food Interactions

There is 1 alcohol/food interaction with insulin inhalation, rapid acting

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide